| 06-Dec-10 |
| Surya Pharmaceutical Ltd has informed BSE that the Board of Directors of the Company at its meeting held on November 03, 2010, inter alia, has the following :
1. The Board has proposed and recommended sub-division of fully paid Equity shares of Rs 10/- each to fully paid Equity Shares of Re 1/- each and consequent alteration in Memorandum & Articles of Association of the Company.
2. An Extra Ordinary General Meeting of the Shareholders of the Meeting has been convened to be held on December 06, 2010, for seeking approval of the Shareholders of the Company.
Surya Pharmaceutical Ltd has informed BSE that an Extra Ordinary General Meeting (EGM) of the members of the Company will be held on December 06, 2010, inter alia, to transact the following :
1. Sub-dividing the equity shares of the company, including the paid-up shares, such that each existing 1 Equity Share of the Company of the face value of Rs. 10/ (Rupees Ten)each be sub-divided into 10 Equity Shares of the face value of Re. 1/-(Rupee One) each and that consequent to the sub-division of the Equity Shares of the Company becoming effective, the Authorised Share Capital of the Company of Rs. 100,00,00,000/- (Rupees One Hundred Crores only) would comprise of 100,00,00,000 (One Hundred Crores) Equity Shares of Re. 1/- each and therefore consequent to the sub-division of the Equity Shares of the Company becoming effective, the existing Clause V of the Memorandum of Association & Articles of Association of the Company.
2. To accord approval to Mr. Suhail Goyal, a relative of Mr. Rajiv Goyal, Chairman and Managing Director of the Company, to hold an office or place of profit as the Associate Director of the Company for a period of five years commencing from November 01, 2010 or from such date as the Central Government may approve, subject to necessary provision & approval.
(As Per BSE Announcement Website dated on 23.11.2010)
Surya Pharmaceutical Ltd has informed BSE that the Extra Ordinary General Meeting (EGM) of the Company was held on December 06, 2010.
(As Per BSE Announcement Dated on 06.12.2010) |
| 30-Jun-10 |
| Board transacted the following :
1. Subject to the approval of the shareholders and other regulatory approvals, if any, the Board has decided to raise upto Rs. 300 crores or equivalent USD from Domestic or International Market by issue of permissible securities for funding its new projects, expansions, diversifications, acquisitions, other business expenses and to augment working capital requirements.
2. Subject to the approval of the shareholders and other regulatory approvals, if any, the Board has decided to raise upto 50 million USD through issue of Foreign Currency Convertible Bonds ('FCCBs') and/or External Commercial Borrowings (ECB).
3. The Extra-Ordinary General Meeting of the shareholders of the Company will be held on June 30, 2010.
Surya Pharmaceutical Ltd has informed BSE that the Extra Ordinary General Meeting (EGM) of the Company was held on June 30, 2010.
(As Per BSE Announcement Dated on 30.06.2010) |
| 14-Mar-09 |
| Surya Pharmaceutical Ltd has informed BSE about the following :
1. Subject to the approval of the shareholders, the company has resolved to increase the authorised capital of the Company from Rs 26.00 Crores, divided into 2,60,00,000 Equity Shares of Rs 10/- each to Rs 50.00 Crores, divided into 5,00,00,000 Equity Shares of Rs 10/- each.
2. Subject to the approval of the shareholders, the Company has resolved to amend Memorandum of Association and Article of Association to give effect to the increase in the authorised capital of the Company.
3. Subject to the approval of the shareholders, SEBI and other regulatory approvals, if any, the Board has approved to issue 47,00,000 equity shares of the Company to M/s Futuristics Garments Pvt Ltd (Promoter Group Company). The issue prices shall be arrived at based on the formula laid down under Chapter XIII of SEBI (DIP) Guidelines (as amended) each ("Warrants") based on relevant date i.e. February 12, 2009. The shares to be issued shall rank pari-passu with the existing shares of the Company including entitlement for payment of dividend.
4. Subject to the approval of the shareholders and other regulatory approvals, if any, the Board has approved to issue upto Rs 100 crores Equity Shares / Securities convertible into Equity Share through Public Offerings / Preferential Allotment or Right Issue or partially through Right Issue and partially. through Public issue to the persons other than existing shareholders in Domestic Market and in International Market upto USD 50 million by way of international offering of Global Depository Receipts ("GDR's") / American Depository Receipts ("ADR's") / Foreign Currency Convertible Bonds ("FCCB's") and / or any other convertible security in one or more trenches. In case FCCBs are issued the same shall be optionally convertible and if the option for conversion is not exercised, the same shall be redeemable after three years / five years as per ECB Guidelines at such price as the Board or the committee constituted by it may think fit in subject to the ECB Guidelines. The issue prices / conversion price / redemption price, as the case may be, shall be decided at the time of offer by the Board / Committee thereof. The shares to be issued upon conversion shall rank pari-passu with the then existing shares of the Company including entitlement for payment of dividend.
5. The Extra-Ordinary General Meeting of the shareholders of the Company will be held on March 14, 2009 to consider the aforesaid matters.
Surya Pharmaceutical Ltd has informed BSE that the Extra Ordinary General Meeting (EGM) of the members of the Company will be held on March 14, 2009, inter alia, to transact the following:
1. To increase the Authorised Share Capital of the Company from Rs 26,00,00,000/- (Rs Twenty Six Crores only) divided into 2,60,00,000 (Two Crores Sixty Lacs) Equity Shares of Rs 10/- (Rs Ten) each to Rs 50,00,00,000/- (Rs Fifty Crores only) divided into 5,00,00,000 (Five Crores) Equity Shares of Rs 10/- (Rs Ten) each and Consequential amendments in the Memorandum & Articles of Association of the Company.
2. To create, offer, issue and allot upto 47,00,000 Convertible Share Warrants at a price of Rs 70/- (inclusive of Rs 10/- face value and Rs 60/- Share Premium) (arrived at based on the formula laid down under Chapter XIII of SEBI (DIP) Guidelines (as amended) each ("Warrants") based on relevant date i.e. February 12, 2009 on a preferential basis in one or more trenches on such terms and conditions and in such manner as the Board may think fit, without offering the same to any other persons who at the date of offer are holders of the Equity Shares; each warrant entitling the holder thereof to apply and be allotted one fully paid Equity Share of Rs 10/- each, at any time not exceeding eighteen months from the date of allotment of the warrants in accordance with the SEBI (DIP) Guidelines and other relevant authorities as may be applicable such that the total number of Equity Shares to be issued by the Company upon conversion of the warrants do not exceed 47,00,000 Equity Shares of Rs 10/- each on such terms and conditions as may be decided and deemed appropriate by the Board of Directors of the Company (ôBoardö which shall be deemed to include any authorised committee thereof) at the time of issue of the allotment to the following Promoter:
i. Name of Allottees: M/s. Futuristics Garments Pvt. Ltd
No. of Warrants: 47,00,000
3. To issue, offer and allot Securities such as Equity Shares, Securities convertible into Equity Shares, Securities convertible into Equity Shares through Public Offering, Preferential Allotment or Rights Issue in Domestic Market upto Rs 100 crores and any securities including Global Depository Receipts and / or American Depository Receipts / Foreign Currency Convertible into equity shares ("Securities") upto Rs USD 50 million to be subscribed by Foreign investors / institutions and / or corporate bodies, mutual funds, banks, insurance companies, trusts and / or individuals or otherwise, whether or not such persons / entities / investors are Members of the Company, whether in Indian Currency or Foreign currency, such issue and allotment shall be made at such price or prices, and on such terms and conditions as the Board may, in its absolute discretion thinks fit, in consultation with the Lead Managers, Underwriters, Advisors or other intermediaries, subject to necessary provisions & approvals.
(As Per BSE Announcement Website dated on 25.02.2009)
Surya Pharmaceutical Ltd has informed BSE that the members at the Extra Ordinary General Meeting (EGM) of the Company held on March 14, 2009, inter alia, have accorded the following:
1. Increased the Authorised Share Capital of the Company from Rs 26,00,00,000/- (Rs Twenty Six Crores only) divided into 2,60,00,000 (Two Crores Sixty Lacs) Equity Shares of Rs 10/- (Rs Ten) each to Rs 50,00,00,000/- (Rs Fifty Crores only) divided into 5,00,00,000 (Five Crores) Equity Shares of Rs 10/- (Rs Ten) each and Consequential amendments in the Memorandum & Articles of Association of the Company.
2. Authority to the Board to create, offer, issue and allot upto 47,00,000 Convertible Share Warrants at a price of Rs 70/- (inclusive of Rs 10/- face value and Rs 60/- Share Premium) (arrived at based on the formula laid down under Chapter XIII of SEBI (DIP) Guidelines (as amended) each ("Warrants") based on relevant date i.e. February 12, 2009 on a preferential basis in one or more trenches on such terms and conditions and in such manner as the Board may think fit, without offering the same to any other persons who at the date of offer are holders of the Equity Shares; each warrant entitling the holder thereof to apply and be allotted one fully paid Equity Share of Rs 10/- each, at any time not exceeding eighteen months from the date of allotment of the warrants in accordance with the SEBI (DIP) Guidelines and other relevant authorities as may be applicable such that the total number of Equity Shares to be issued by the Company upon conversion of the warrants do not exceed 47,00,000 Equity Shares of Rs 10/- each on such terms and conditions as may be decided and deemed appropriate by the Board of Directors of the Company ("Board" which shall be deemed to include any authorised committee thereof) at the time of issue of the allotment to the following Promoter:
i. Name of Allottees: M/s. Futuristics Garments Pvt. Ltd
No. of Warrants: 47,00,000
3. Authority to the Board to issue, offer and allot Securities such as Equity Shares, Securities convertible into Equity Shares, Securities convertible into Equity Shares through Public Offering, Preferential Allotment or Rights Issue in Domestic Market upto Rs 100 crores and any securities including Global Depository Receipts and / or American Depository Receipts / Foreign Currency Convertible into equity shares ("Securities") upto Rs USD 50 million to be subscribed by Foreign investors / institutions and / or corporate bodies, mutual funds, banks, insurance companies, trusts and / or individuals or otherwise, whether or not such persons / entities / investors are Members of the Company, whether in Indian Currency or Foreign currency, such issue and allotment shall be made at such price or prices, and on such terms and conditions as the Board may, in its absolute discretion thinks fit, in consultation with the Lead Managers, Underwriters, Advisors or other intermediaries, subject to necessary provisions & approvals.
(As Per BSE Announcement Dated on 16/03/2009) |
| 31-Aug-06 |
| Surya Pharmaceutical Ltd has informed BSE that the members at the Extra-Ordinary General Meeting (EGM) of the Company held on August 31, 2006 have approved the appointment of M/s A A D & Associates, Chartered Accountants, Chandigarh, as Statutory Auditors. |
| 25-Feb-06 |
| Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors at their meeting held on January 28, 2006 have interalia approved the following :-(i) subject to the approval of the shareholders, the
Company has resolved to increase the authorised capital of the company from Rs.20.00 Crores, divided into 2,00,00,000 Equity shares of Rs.10.00 each, to Rs.26.00 Crores, divided into 2,60,00,000 Equity Shares of Rs.10.00 each. (ii) Subject to the approval of the shareholders the Company has resolved to amend Memorandum of Association and Articles of Association to
give effect to the increase in the authorised capital of the company. (iii) Subject to the approval of the shareholders and other regulatory approvals, if any, the Board has approved to issue up to USD 50 million by way of international offering of Global Depository Receipts ("GDR's") / American Depository Receipts ("ADR's") / Foreign Currency Convertible Bonds ("FCCB's") and / or any other convertible security in one or more tranches.
In case FCCB are issued the same shall be optionally convertible and if the option for conversion is not exercised, the same shall be redeemable after three years / five years as per ECB Guidelines at such price as the Board
or the committee constituted by it may think fit in subject to the ECB Guidelines. The issue prices / conversion price / redemption price, as the case may be, shall be decided at the time of offer by the Committee constituted by the Board. The shares to be issued upon conversion shall rank pari-passu with then existing shares of the Company including entitlement for payment of dividend. (iv) The EGM of the shareholders of the Company will be held on February 25, 2006, to consider the aforesaid
matters. Further, the Board has approved the plan to leverage the synergies by making focused investment in healthcare segments. The Board has also approved the proposal to set up / acquire a pharmaceutical manufacturing unit in Europe.
EGM 25/02/2006
To consider inter alia the following business:
1. Increase in Authorised Share Capital of the Company from Rs 20,00,00,000/- divided into
2,00,00,000 Equity Shares of Rs 10/- each to Rs 26,00,00,000/- divided into 2,60,00,000 Equity
Shares of Rs 10/- each, and consequential amendment in Memorandum & Article of Association of the Company.
2. To issue, offer and allot, in domestic / international offering any securities including GlobalDepository Receipts and / or American Depository Receipts / Foreign Currency Convertible
Bonds convertible into equity shares at the option of the Company and / or at the option of holders of the security and / or any other Security linked to equity shares or any instruments representing convertible securities such as convertible bonds convertible into equity shares ("Securities") whether in Indian Currency or Foreign currency, such issue and allotment shall be made at such time or times in one or more tranche or tranches, at par or at such price or prices and on such terms and conditions as the Board may in its absolute discretion thinks fit, in consultation with Lead Managers, Underwriters, Advisors or other intermediaries, provided however that the amount to be raised through issue of securities shall not exceed US $ 50 millions.
3. To mortgage and / or charge, in such form and manner which the Board may determine on all or any of the movable and / or immovable properties of the Company both present and future and / or the whole or any Part of the undertaking of the Company availed / to be availed from the Company's lenders byway of Loan(s) subject to the limits approved under section 293(1)(d) of the Companies Act, 1956 together with interest liquidated damages, commitment charges, premium and all other charges and expenses in respect of the said loan /
borrowings and containing such specific terms & conditions and covenants in respect of enforcement of security as may be stipulated in this behalf and agreed to between Board of Directors or Committee thereof and the lenders(s), subject to necessary approvals & provisions.
Further, to borrow money, whether secured or unsecured, whether from India or abroad, whether from banks, corporates, public or private financial institutions or any other companies, firms or individuals through public offering or private placement in any manner, for and on behalf of the Company, from time to time, any sum or sums of money, not exceeding Rs 5000 million (A part from temporary loans obtained from the Company's Bankers in the ordinary Course of Business) in Indian or any other equivalent freely convertible
currency, subject to necessary approvals & provisions.
(As per BSE Bulletin dated on 22/02/2006)
The company has informed that the members at the Extra Ordinary General Meeting (EGM) of the Company held on February 25, 2006, inter alia, have accorded to the following:
1. Increase in Authorised Share Capital of the Company from Rs 20,00,00,000/- divided into 2,00,00,000 Equity Shares of Rs 10/- each to Rs 26,00,00,000/- divided into 2,60,00,000 Equity Shares of Rs 10/- each and consequential amendment in Memorandum & Article of Association of the Company.
2. Authority to Board to issue, offer and allot, in domestic / international offering any securities including Global Depository Receipts and / or American Depository Receipts / Foreign Currency Convertible Bonds convertible into
equity shares at the option of the Company and / or at the option of holders of the security and / or any other Security linked to equity shares or any instruments representing convertible securities such as convertible bonds convertible
into equity shares ("Securities") whether in Indian Currency or Foreign currency, such issue and allotment shall be made at such time or times in one or more tranche or tranches, at par or at such price or prices and on such terms and
conditions as the Board may in its absolute discretion thinks fit, in consultation with Lead Managers, Underwriters,Advisors or other intermediaries, provided however that the amount to be raised through issue of securities shall not
exceed US $ 50 millions.
3. Authority to Board to mortgage and / or charge, in such form and manner which the Board may determine on all or any of the movable and / or immovable properties of the Company both present and future and / or the whole or any Part of the undertaking of the Company availed / to be availed from the Company's lenders by way of Loan(s) subject to the limits approved under section 293(1)(d) of the Companies Act, 1956 together with interest liquidated damages, commitment charges, premium and all other charges and expenses in respect of the said loan / borrowings and
containing such specific terms & conditions and covenants in respect of enforcement of security as may be stipulated in this behalf and agreed to between Board of Directors or Committee thereof and the lenders(s), subject to necessary
approvals & provisions.
Further, to borrow money, whether secured or unsecured, whether from India or abroad, whether from banks, corporates, public or private financial institutions or any other companies, firms or individuals through public offering
or private placement in any manner, for and on behalf of the Company, from time to time, any sum or sums of money, not exceeding Rs 5000 million (A part from temporary loans obtained from the Company's Bankers in the ordinary Course of Business) in Indian or any other equivalent freely convertible currency, subject to necessary approvals & provisions.
(As per BSE Bulletin dated on 02/03/2006) |